Expression analysis of 6p22 genomic gain in retinoblastoma
โ Scribed by Marija Orlic; Clarellen E. Spencer; Lisa Wang; Brenda L. Gallie
- Book ID
- 102220562
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 438 KB
- Volume
- 45
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
To identify gene(s) targeted by 6p22 genomic gain, present in more than 50% retinoblastoma tumors, we used realโtime RTโPCR to quantify the expression of seven genes in normal human retina and retinoblastoma. Six genes are located in the quantitative multiplex PCRโdefined 0.6 Mb minimal region of gain at 6p22 (DEK, AOF1, TPMT, NHLRC1, KIF13A, and NUP153), and E2F3 is 2 Mb away from the minimal region of gain on 6p22. E2F3, DEK, KIF13A, and NUP153 were most frequently overexpressed in retinoblastoma with 6p genomic gain, compared with the normal adult human retina. E2F3 and DEK mRNA levels were increased in all human tumors showing 6p22 gain, as well as in mouse retinoblastoma induced by SV40 large T antigen expression in developing retina, compared with the normal controls (adult human retina and 7โdayโold mouse retina, respectively). Only DEK showed statistically significant correlation of expression and genomic copy number (P = 0.019). E2F3 and DEK, but not NUP153, showed developmental regulation. E2F3 and DEK mRNA overexpression was always associated with protein overexpression, determined by immunoblotting or immunofluorescent staining of primary tumors, relative to the adjacent normal retina. E2F3 was strongly expressed in actively proliferating cells, while DEK was overexpressed in all tumor cells. Taking into account the proliferationโpromoting role of E2F3, implication of E2F3 in bladder and prostate cancer, and the translocation and overexpression of DEK in leukemia, we conclude that either DEK or E2F3 (or both) are targeted by the 6p22 gain in retinoblastoma. ยฉ 2005 WileyโLiss, Inc.
๐ SIMILAR VOLUMES